Onsynergy’s Post

The European Commission has published a report providing an overview of the enforcement of EU antitrust and merger rules by the European Commission and the national competition authorities in the pharmaceutical sector between 2018 and 2022. The report shows that active enforcement of antitrust and merger rules continues to play an important role in delivering European patients' access to a wider choice of affordable and innovative medicines. In particular, it has helped to achieve this goal during the challenging period of the coronavirus pandemic. According to the findings of the report, antitrust enforcement has contributed to fairer prices for medicines, and merger control has kept medicines' prices lower and markets competitive. To read the whole report 👉 https://europa.eu/!G8gKHH #pharmaceuticals #competitionlaw #antitrust #mergers

The European Commission published the Science, Research and Innovation Performance Report. The report highlights: ➡ EU research & innovation ecosystem (R&I) remains underutilized ➡ Divide in R&I for activities/support ➡ Gap with the rest of the world raising private investments The report offers several recommendations: ➡ Improve the sector of research universities ➡ Allocate a fraction of R&I funds to government research labs and introduce accountability reforms ➡ Create an Advanced Research Projects Agency for Health (ARPA) modeled after the US ARPA-H Read more > https://hubs.li/Q02Fw8Qv0 #ResearchAndInnovation #pharmaceutical

The European Commission published the Science, Research and Innovation Performance Report. The report highlights: ➡ EU research & innovation ecosystem (R&I) remains underutilized ➡ Divide in R&I for activities/support ➡ Gap with the rest of the world raising private investments The report offers several recommendations: ➡ Improve the sector of research universities ➡ Allocate a fraction of R&I funds to government research labs and introduce accountability reforms ➡ Create an Advanced Research Projects Agency for Health (ARPA) modeled after the US ARPA-H Read more > https://hubs.li/Q02FwbZR0 #ResearchAndInnovation #pharmaceutical

🔍 European Parliament Extends IVDR Compliance Deadlines 🔍 🇪🇺 The European Parliament has adopted measures to give IVD firms more time to meet the In Vitro Diagnostic Medical Devices Regulation (IVDR) requirements, providing a phased introduction of the European Database on Medical Devices (Eudamed). 📅 Key Timelines: 👉High risk devices: Compliance by Dec 2027 👉Moderate risk devices: Compliance by Dec 2028 👉Lower risk devices: Compliance by Dec 2029 👉Mandatory use of Eudamed parts starting 2026 🤔 This development is especially noteworthy as we anticipate the upcoming FDA LDT rule, which is expected to include aggressive timelines. https://lnkd.in/dpm8_SCG #Healthcare #IVDR #MedicalDevices #RegulatoryUpdate #Eudamed #FDA

Have you ever heard the term called Amygdala Highjack or Amygdala Leakage? If not, please watch the video to learn more about the concept and how it can help you improve your communication and relations with others, especially your loved ones... What do you think???   Should you need to assess or develop your team members, please do let us know how we (www.assesspro.in) can help you.   #assessments #assessmentcenter #lederashippipeline #managerialeffectiveness #leadershipdevelopment  #assessmentanddevelopmentcenter #linkedin #assesspro #competencyframework #competencyassessment #hiring #highpotentials #promotions #pharma #pharmaceuticals #competency #macleods #sunpharma #cipla #glenmark #mankind #alkem #abbott #zydus #drreddys #glaxo #ipca #pfizer #micro #sanofi #usv #torrent #cadila #lupin #intas https://lnkd.in/dH_U6r8F

Have you ever heard the term called Amygdala Highjack or Amygdala Leakage? If not, please watch the video to learn more about the concept and how it can help you improve your communication and relations with others, especially your loved ones...

My latest article.

My latest article.

My latest article.